Feeds:
Posts
Comments

Posts Tagged ‘Provenge’

PUGET SOUND BUSINESS JOURNAL: The US drug company that is about to produce the world’s most promising immuno-therapy prostate cancer treatment – Provenge – has reported a second-quarter loss of $126.7 million. READ MORE>

Read Full Post »

NEW PROSTATE CANCER INFOLINK: A screening test that distinguishes between indolent and harmful prostate cancer, better drugs, and more immuno-therapy treatments (like Provenge) for advanced cancer – these are priorities the prostate community has chosen in a poll. READ MORE>

Read Full Post »

XCONOMY SEATTLE: Dendreon’s immune-stimulating therapy for prostate cancer, called Provenge, was able to improve median survival time by 4.1 months, and lowered the risk of death by 22.5 percent, according to long-awaited clinical trial results presented at the American Urological Association annual meeting today. READ MORE> and HERE>

Read Full Post »

US COMPETITIVE ENTERPRISE INSTITUTE: RESEARCHERS announced very favourable results for the drug Provenge at this week’s meeting of the American Association of Cancer Research. But that only highlights the shortcomings of the Food and Drug Administration, which has refused to approve the drug, despite previous studies indicating its safety and effectiveness. READ MORE>

Read Full Post »

« Newer Posts